and anemia determines tacrolimus exposure. 5 Enzymes in the cytochrome P450 (CYP) 3A family play an important role in the metabolism of tacrolimus. It metabolized both first-pass metabolism and systemic clearance of the drug, 6 which are responsible for the intra-and interindividual variability in blood concentrations of tacrolimus. Variant alleles for CYP3A5 (*3, *6, or *7) may result in protein truncation and a severe decrease in functional CYP3A5 enzyme, or nonfunctional proteins. 7 Although CYP3A5*6 and CYP3A5*7 alleles result in decreased CYP3A5 activity, they are less frequently examined because of the rarity of these 2 alleles in most populations. 8 The CYP3A5 *3 allele has received the most attention. CYP3A5*1/*3 is believed to explain up to 45% of the variability in tacrolimus dose in Caucasian patients after kidney transplantation. 9 The CYP3A5*3
allele was reported to be detected in 80%-85% Caucasian, 73%
of Chinese, 71% of Japanese, 70% of Korean, and 27% of African American individuals. 10, 11 Individuals homozygous for the CYP3A5*3
allele are referred to as CYP3A5 nonexpressers, while individuals carrying at least 1 CYP3A5*1 allele are known as CYP3A5 expressers. The CYP3A5 expressers would require a 1.5-2 times starting dose than the nonexpressers to reach the same exposure. 6 It was reported that the proportion of patients on target increased and the dose-adjusted trough concentrations significantly decreased when the tacrolimus dosing was guided by CYP3A5 genotypes. 12 A wider and more appropriate deployment of genetic testing in the clinical setting would lead to an optimized tacrolimus prescribing. 13 More laboratories are introducing clinical pharmacogenetic testing of tacrolimus using in-house assays or one of the expanding ranges of commercially available genotypic and phenotypic kits. As a result of the influence on clinical treatment decisions, the genotyping tests applied in clinical settings must have the ability to produce results that are accurate, reliable as well as readily available. In order to obtain the interlaboratory consistency according to accepted predefined standards of quality, External Quality Assessment (EQA) of the detecting laboratories is often used as a critical step to harmonize and standardize the testing results. 14 Diagnostic and clinical reality is reflected as closely as possible within the EQA program by exposing and addressing existing shortcomings in both genotyping and result reporting. 15 Analytical as well as pre-analytical and postanalytical phases of the laboratory process will be assessed. Therefore, the National Center for Clinical Laboratories established the first tacrolimus-related CYP3A5 genotyping EQA exercise with the purpose of evaluating the achievement of laboratories providing CYP3A5 testing service in
China. This study describes the EQA results of laboratories routinely performing pharmacogenetic testing, evaluates the results reporting and interpretation, and provides recommendations to improve the reproducibility and comparability of pharmacogenetic testing.
| MATERIAL S AND ME THODS

| Scheme organization
Two hundred and thirty four invitation letters were sent to laborato- 
| Preparation of proficiency panel
Wild-type CYP3A5 cell lines (GM19178, GM23275) and CYP3A5*3 allele cell lines (GM12003, GM18565, GM19147, GM10847, GM17244, GM17702, and GM18992) were purchased from Coriell
Cell Repositories (Camden, NJ, USA) ( 
| Scoring of the reports
Each registered laboratory was requested to submit result of the first sample "C1701" with the reporting template which was normally used on their routine basis. The performance of the reports compi- were scored 1 point, items that were present but ambiguously present were scored 0.5 point, and no point was awarded if the items were not described or wrongly described.
| Statistical analysis
The testing results were evaluated by a board of experts from NCCL.
A genotype comparison with the NCCL reference laboratory was conducted to determine the accuracy of each participant. A minimum of 80% reporting accuracy is required for a proficient dataset.
Test results were graded as competent, improvable, and unaccep- 
| RE SULTS
| Participating groups and methodologies
Fifteen of the 33 registers who submitted the final results before the closing date were hospital laboratories, and the other 18 were commercial laboratories. Of the 15 hospital laboratories, 7 were from the pharmaceutical departments, 4 were from the clinical laboratories, and 4 were from molecule diagnostic centers. Twenty-eight laboratories offer tests for clinical use. Eleven laboratories (33.3%)
were accredited or certificated according to at least 1 of the 3 international standards. Twelve laboratories submitted the number of specimens processed by the laboratories per month, and the average was 76 (range: 3-500).
A variety of techniques were used in the CYP3A5 genotyping.
Pyrosequencing was the most frequently used method (12 laboratories 36.3%) ( 
| Performance of CYP3A5 genotyping
The test result of each sample was evaluated. A total of 330 samples were tested, 315 of which were correctly genotyped. Thirty The performances of different testing methodologies were assessed ( Table 2 ). All of the errors were reported by the laboratories using LDTs based on Sanger sequencing method and MALDI-TOF-MS. The results with all of the challenges correctly identified were submitted by the laboratories using pyrosequencing, real-time PCR, DNA microarray, NGS, ARMS, and SBH. The analytical performance of different CYP3A5 testing methods was summarized in Table 2 . The overall genotyping sensitivity and specificity were both good (95.9% and 95.3%, respectively). The CYP3A5 genotyping performance between commercial kits and LDTs was compared, but no distinct difference in testing accuracy was observed (P = .247).
| Results reporting
Reports for results of specimen C1701 were submitted by 28 of the 33 registered laboratories, and 5 laboratories submit no report for unknown reason. The reports were evaluated according to the criteria mentioned previously. The average score of the reports was 7.68 of 9, ranging from 4 to 9 points. The coverage of the nine items present in the laboratories' submitted reports is demonstrated in Figure 1 .
Critical elements such as name/address of testing laboratory, detecting method, and therapeutic recommendations were missing in 64.0%, 20.0%, and 12.0% of the reports, respectively. Twenty-four percent of laboratories ambiguously described the testing method as "sequencing" or "PCR sequencing." Patient's name, interpretation of the results, date of the report, and the signature of laboratory director or designee were not included in 4% of the reports. One laboratory reported the right genotype, but the wrong interpretation of the result by recommending an increased tacrolimus initial dose for CYP3A5 nonexpressers (with CYP3A5*3/*3 genotype).
| D ISCUSS I ON
Precision medicine constitutes a promising approach for maximizing treatment efficacy and minimizing toxicity, for facilitating efficient healthcare delivery, and generating cost savings. Pharmacogenetic studies of tacrolimus have significantly added to our understanding of tacrolimus pharmacology and the treatment decisions. 21 Preprescription genotyping of CYP3A5 was used for initial dose estimating of tacrolimus and a faster target concentration achievement. 6 In this study, we report the first EQA that evaluated the performance of laboratories providing CYP3A5 testing service in China.
The overall performance was good and most of the laboratories met the criteria for the accurate genotyping. However, 3 laboratories produced mistakes. A possible explanation for the mistakes might be that the LDTs have not been validated in these laboratories. Genome Reference Assembly as a reference sequence when naming sequence variants. 20 However, none of the test reports fulfilled the recommended variant nomenclature. Many laboratories reported the testing method as "sequencing," but did not specify which sequencing technique (such as Sanger sequencing or pyrosequencing) was used.
It is necessary to have the method specified because of the variety of the methods that can be used. 24 Many tests have limitations that make them subject to false-positive or false-negative results. Therefore, as a result of the different performance characteristics of each method and the clinical influence of an incorrect genotyping, it is worthwhile to have these limitations described in the report.
Another integral part of the report is the clinical interpretation of results, which involves demonstrating the meaning of the result for the particular patient, either generally or patient-specifically. 24 In our study, the interpretation of the results and therapeutic recom- genotype, while the historical term "extensive metabolizer" that reflects a normal function was too confusing for clinicians. "Normal metabolizer" was chosen by the experts from a CPIC project that is aimed to reach a consensus on the employment of standard terms for both pharmacogenetic allele function and corresponding phenotypes. 26 The term "extensive metabolizer" that was most frequently used in the submitted reports in our EQA will no longer be recommended.
A complete report with all information included may reduce the possibility of making mistakes by reminding the reviewer that the elements in the report should coordinate with each other before the report is released. An example of tacrolimus-related CYP3A5 genotyping report, which fulfills the pharmacogenetic test reporting recommendations, is shown (Table S1) The limitation of our study is that the system did not access the analytical step of DNA extraction. Genomic DNA extracted from cell lines with variants was used, as it was difficult to get enough volume of well-characterized clinical samples.
In conclusion, according to our research, the overall performance of the first Chinese CYP3A5 EQA was good. Mistakes were produced by a few laboratories either in genotyping with in-house tests or the interpretation of genotype information. Although most of the participants submitted the written reports, not all clinically important items eventually reached an acceptable level. The test reports could be greatly improved using HGVS nomenclature when naming variants. Periodical EQA and continued education in the pharmacogenetic testing field are essential to make sure that the clinician has the accurate information to refer when they put genotype-guided tacrolimus dosing into practice. All laboratories conducted pharmacogenomic testing should regularly participate in EQA programs to maintain high-quality performance.
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